Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. Almhanna K, et al. Among authors: starling n. Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19. Invest New Drugs. 2017. PMID: 28527133 Clinical Trial.
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Starling N, Vázquez-Mazón F, Cunningham D, Chau I, Tabernero J, Ramos FJ, Iveson TJ, Saunders MP, Aranda E, Countouriotis AM, Ruiz-Garcia A, Wei G, Tursi JM, Guillen-Ponce C, Carrato A. Starling N, et al. Ann Oncol. 2012 Jan;23(1):119-127. doi: 10.1093/annonc/mdr046. Epub 2011 Mar 29. Ann Oncol. 2012. PMID: 21447616 Free article. Clinical Trial.
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I. Watkins DJ, et al. Among authors: starling n. Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6. Eur J Cancer. 2014. PMID: 24613126 Clinical Trial.
Pharmacotherapy for oesophagogastric cancer.
Jackson C, Starling N, Chua YJ, Cunningham D. Jackson C, et al. Among authors: starling n. Drugs. 2007;67(17):2539-56. doi: 10.2165/00003495-200767170-00006. Drugs. 2007. PMID: 18034590 Review.
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Cunningham D, et al. Among authors: starling n. N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149. N Engl J Med. 2008. PMID: 18172173 Free article. Clinical Trial.
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. Starling N, et al. Br J Cancer. 2009 Jun 2;100(11):1725-30. doi: 10.1038/sj.bjc.6605070. Epub 2009 May 12. Br J Cancer. 2009. PMID: 19436301 Free PMC article. Clinical Trial.
132 results